Luminopia Shows Promise as First Non-Surgical Treatment for Intermittent Exotropia: Study
Luminopia therapy significantly improved distance control scores after 3 months in young children with intermittent exotropia. Findings from this pilot study suggest it could become the first FDA-cleared, non-surgical treatment option for managing this condition.
The study suggests that the binocular treatment may improve eye movement control in this difficult-to-treat condition.
The study analyzed 10 children aged 4-7 with unilateral IXT, who were prescribed one hour per day of Luminopia therapy, six days per week and achieved ≥50% adherence. Control scores and stereopsis were measured at baseline, after three months of treatment, and after a three-month washout period (i.e., six months after baseline).
Key findings include:
- Distance control scores improved significantly from a mean of 2.9 at baseline to 1.7 after three months (p=0.01).
- Improvement at three months did not regress at six months, suggesting a potential sustained benefit.
- There was a trend towards improvement in stereoacuity as well.
"While this is a small pilot, these findings are exciting because they suggest that dichoptic therapy delivered via Luminopia may improve control in children with IXT," said Dr. Silverstein, study author. "This lays the groundwork for Luminopia to potentially become the first non-surgical, FDA-cleared treatment for IXT."
"This pilot study offers promising early data and underscores the potential of dichoptic therapy to transform care for children with intermittent exotropia," said Scott Xiao, founder and CEO of Luminopia. "The findings also validate the broader therapeutic potential of our platform in treating conditions at the intersection of the visual system and the brain."
